Immunodeficiency 9 (IMD9) Cell Models for Research

Immunodeficiency 9 (IMD9) is an extremely rare primary immunodeficiency disorder caused by mutations in the CD3E gene. The exact prevalence is unknown, but only a handful of cases have been reported worldwide. Patients typically present in infancy with severe recurrent infections, autoimmunity, and failure to thrive. Without hematopoietic stem cell transplantation, the condition is often fatal in early childhood. The rarity and severity underscore the need for accurate models to study disease mechanisms and test therapies.

IMD9 provides a unique opportunity to study T cell development and signaling. The CD3E protein is a critical component of the T cell receptor (TCR) complex, and its loss leads to a complete block in T cell maturation. Research models are essential to understand the molecular basis of TCR signaling, evaluate potential gene therapy approaches, and screen for drugs that might bypass the defect. Public datasets on CD3E mutations are sparse, but the availability of gene-edited cell lines can accelerate functional studies.

While IMD9 is not a cancer, the affected pathways are central to immune cell function. The TCR signaling pathway is disrupted, leading to impaired T cell activation and proliferation. Key steps include:

1. TCR engagement by antigen-MHC complexes.

2. Recruitment of CD3 subunits (including CD3E) to the TCR complex.

3. Activation of Lck and ZAP-70 kinases.

4. Phosphorylation of LAT and SLP-76, leading to downstream signaling cascades (e.g., Ras-MAPK, PLCγ-Ca2+, NFAT, NF-κB).

In IMD9, loss of CD3E prevents proper TCR assembly and signaling, resulting in a severe combined immunodeficiency (SCID) phenotype.

Data from ClinVar and NCBI Gene indicate that all reported IMD9 cases involve biallelic mutations in CD3E.

The primary deregulated network is the TCR signaling pathway. Key nodes include:

• • TCR complex: Composed of TCRα/β (or γ/δ) and CD3γ/δ/ε/ζ. CD3E is essential for assembly and signal transduction.
• • Lck: A Src family kinase that phosphorylates ITAMs on CD3 subunits.
• • ZAP-70: Binds to phosphorylated ITAMs and activates downstream effectors.
• • LAT and SLP-76: Adaptor proteins that nucleate signaling complexes.
• • PLCγ1: Generates IP3 and DAG, leading to Ca2+ flux and PKC activation.
• • NFAT, NF-κB, AP-1: Transcription factors that drive T cell activation and proliferation.

Loss of CD3E disrupts this entire network, leading to a block in T cell development at the double-negative stage.

Organoids: While intestinal organoids are not directly relevant, T cell organoids (thymic organoids) can be generated from patient-derived iPSCs or gene-edited stem cells to study T cell development. These 3D models recapitulate thymic architecture and allow testing of gene therapy approaches.

Animal models for IMD9 include:

• • Cd3e knockout mice: These mice exhibit a severe block in T cell development, mimicking the human condition. They are used to study TCR signaling and test gene therapy strategies.
• • Humanized mice: Immunodeficient mice (e.g., NSG) engrafted with human hematopoietic stem cells can be gene-edited to introduce CD3E mutations, allowing study of human T cell development in vivo.
• • Zebrafish models: Although less common, zebrafish with cd3e mutations have been used to study T cell development.

PDX models are not applicable for IMD9 as it is not a cancer.

CRISPR-Cas9 gene editing enables the creation of isogenic cell lines with specific CD3E mutations. For example:

• • CD3E knockout Jurkat cells: Generated by introducing frameshift mutations in the CD3E gene, resulting in loss of protein expression. These cells can be used to study TCR signaling defects and screen for compounds that rescue signaling.
• • CD3E point-mutation knock-in lines: Introduce specific patient mutations (e.g., p.Arg90Trp) to study their impact on protein function.

These gene-edited models are commercially available from various sources and are sequence-verified to ensure accuracy. They provide a renewable and reproducible platform for functional studies, drug screening, and target validation.

Gene-edited cell lines with CD3E knockout or knock-in mutations allow researchers to:

• • Validate the functional impact of specific CD3E mutations on TCR signaling.
• • Perform rescue experiments by reintroducing wild-type or mutant CD3E to assess complementation.
• • Identify downstream effectors and modifiers through CRISPR screens in these backgrounds.

For example, a CD3E knockout Jurkat line can be used to screen for genes that, when knocked out, restore TCR signaling, revealing potential therapeutic targets.

Isogenic pairs (wild-type vs. CD3E knockout) are powerful tools for drug screening:

• • High-throughput screens can identify compounds that activate TCR signaling in the absence of CD3E, potentially bypassing the defect.
• • Resistance mechanisms can be studied by exposing cells to drugs and selecting for resistant clones, then sequencing to identify mutations that restore signaling.

These models are also useful for testing gene therapy approaches, such as lentiviral delivery of functional CD3E.

CRISPR synthetic lethality screens in CD3E-deficient cells can identify genes that are essential only in the absence of CD3E. These genes could serve as biomarkers for disease progression or as targets for therapeutic intervention. For example, if a kinase is synthetically lethal with CD3E loss, inhibitors of that kinase might selectively kill IMD9 cells while sparing normal T cells.